首页> 外文期刊>Human Pathology >Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
【24h】

Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?

机译:增生性黑色素瘤亚型中的神经纤维蛋白蛋白损失:暗示NF1等位基因损失是独特的遗传驱动因素吗?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Loss of the NF1 allele, coding for the protein neurofibromin, and polymorphism in the protooncogene RET (RETp) are purportedly common in desmoplastic melanoma (DM). DM is categorized into pure (PDM) and mixed (MDM) subtypes, which differ in prognosis. Most NF1 mutations result in a truncated/absent protein, making immunohistochemical screening for neurofibromin an ideal surrogate for NF1 allelic loss. Using antineurofibromin, our aims were to ascertain the incidence of neurofibromin loss in DM subtypes and to evaluate the relationship with RET, perineural invasion (PNI) and established histopathologic prognosticators. A total of 78 archival samples of DM met criteria for inclusion (54 cases of non-DM serving as controls). Immunohistochemistry was performed for neurofibromin, whereas direct DNA sequencing was used for RETp and BRAF mutation status. Statistical analyses included chi(2) test as well as Fisher exact test. Neurofibromin loss was more common in DM than non-DM (69% versus 54%; P = .02). In DM, significant differences in neurofibromin loss were noted in the following: non head and neck versus head and neck biopsy site (88% versus 55%) and PDM versus MDM variants (80% versus 56%). No significant associations were noted with sex, presence of a junctional component, Breslow depth, ulceration, mitoses, host response, RETp, BRAF status, or PNI. RETp was marginally associated with PNI-positive DM versus PNI-negative DM (36 versus 18%; P = .08). Our findings, the largest to date investigating neurofibromin in DM, validate the incidence of NF1 mutations/allelic loss in DM and suggest that the DM subtypes have distinct genetic drivers. Published by Elsevier Inc.
机译:据称,原癌基因RET(RETp)中编码蛋白质神经纤维蛋白的NF1等位基因的缺失和多态性在增生性黑色素瘤(DM)中很常见。 DM分为纯(PDM)和混合(MDM)亚型,它们在预后方面有所不同。大多数NF1突变会导致蛋白质被截断/缺失,从而使神经纤维蛋白的免疫组化筛选成为NF1等位基因缺失的理想替代物。我们使用抗神经纤维蛋白的目的是确定DM亚型中神经纤维蛋白损失的发生率,并评估与RET,神经周围浸润(PNI)的关系并建立组织病理学预后指标。总共78份DM档案样本符合纳入标准(54例非DM用作对照)。免疫组化用于神经纤维蛋白,而直接DNA测序用于RETp和BRAF突变状态。统计分析包括chi(2)检验以及Fisher精确检验。 DM中神经纤维蛋白的丢失比非DM更常见(69%比54%; P = .02)。在DM中,以下发现了神经纤维蛋白损失的显着差异:非头颈与头颈活检部位(88%对55%)以及PDM对MDM变异(80%对56%)。没有发现与性别,交界成分的存在,Breslow深度,溃疡,有丝分裂,宿主反应,RETp,BRAF状态或PNI有显着相关性。 RETp与PNI阳性DM相对于PNI阴性DM的相关性很小(36%vs 18%; P = 0.08)。我们的发现是迄今为止最大的研究DM中神经纤维蛋白的研究,它验证了DM中NF1突变/等位基因缺失的发生率,并表明DM亚型具有独特的遗传驱动力。由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号